Trial Profile
A Prospective, Observational, Single-center Post-marketing Surveillance Study of Telbivudine in Chronic Hepatitis B Adults With HBeAg Positive/Negative.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Mar 2016
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 26 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jul 2011 Planned End Date changed from 1 Nov 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 10 Sep 2009 New trial record